Jazz Pharmaceuticals (JAZZ) AI Stock Analysis

• Market Cap: $7.87B
• Dividend Yield: N/A
• Average Volume (3M): 801.79K
• Price to Earnings (P/E): 15.6
• Beta (1Y): 0.76
• Revenue Growth: 4.52%
• EPS Growth: -205.13%
• Country: US
• Employees: 2,800
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): -8.25
• Shares Outstanding: 60,658,810
• 10 Day Avg. Volume: 759,354
• 30 Day Avg. Volume: 801,793
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.30
• Enterprise Value/Revenue: 2.51
• Enterprise Value/Gross Profit: 2.83
• Enterprise Value/Ebitda: 22.94
• 1Y Price Target: $184.69
• Price Target Upside: 44.27% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 15

• Rating: 64 Neutral
• Price Target: $126.00 ▼(-1.58% Downside)

Jazz Pharmaceuticals' overall stock score reflects strong technical indicators and positive earnings call sentiment, tempered by valuation concerns and financial performance risks. The company's revenue growth and upcoming regulatory milestones are promising, but profitability challenges and high leverage remain significant risks.

Positive Factors

Market Opportunity

Modeyso could be at least a $300M opportunity in the US alone.

Product Launch

Modeyso represents the first FDA approved targeted therapy for H3 K27M-mutant Diffuse Midline Glioma.

Negative Factors

Clinical Trial Challenges

A pause in enrollment for the Phase 3 ACTION study was flagged to ensure study integrity, affecting the timeline.

Market Limitations

Modeyso uptake is expected to be largely restricted to academic centers due to the need for biopsy.

Jazz Pharmaceuticals Business Overview & Revenue Model

Company Description

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing innovative products to address unmet medical needs. The company operates primarily in the therapeutic areas of neuroscience and oncology, delivering a range of medications designed to improve patients' lives. Key products include Xyrem for narcolepsy, Sunosi for excessive daytime sleepiness, and Defitelio for severe hepatic veno-occlusive disease.

How the Company Makes Money

Jazz Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products. The company has a robust portfolio of approved therapies, which contribute to significant sales in both domestic and international markets. Key revenue streams include direct sales of its proprietary medications, royalties from licensing agreements, and collaborations with other pharmaceutical companies. The company also invests in research and development to create new products and expand its existing offerings, which can lead to additional revenue through market exclusivity and patent protection. Strategic partnerships and acquisitions further enhance its product pipeline and market reach, contributing to sustained financial growth.

Jazz Pharmaceuticals Financial Statement Overview

Summary

Jazz Pharmaceuticals shows strong revenue growth and efficient cash flow management. However, profitability challenges and high leverage present potential risks. The company needs to address its operational inefficiencies to improve margins and reduce financial risk.

Income Statement

Jazz Pharmaceuticals has shown a strong revenue growth rate of 53.8% in the TTM, indicating robust top-line expansion. However, the company is currently experiencing negative net profit margins, which is a concern for profitability. The gross profit margin remains high, reflecting efficient cost management, but the negative EBIT margin suggests operational challenges.

Balance Sheet

The company's debt-to-equity ratio is relatively high at 1.47, indicating significant leverage, which could pose financial risks. The return on equity is negative, reflecting recent net losses. However, the equity ratio is stable, suggesting a balanced asset structure.

Cash Flow

Jazz Pharmaceuticals maintains a strong operating cash flow, with a high free cash flow to net income ratio, indicating efficient cash generation relative to earnings. Despite a decline in free cash flow growth, the company has a solid cash flow position, supporting its operations and potential investments.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.09B	4.07B	3.83B	3.66B	3.09B	2.36B
Gross Profit	3.63B	3.62B	3.40B	3.12B	2.65B	2.21B
EBITDA	447.10M	1.52B	1.45B	1.47B	1.03B	1.04B
Net Income	-404.84M	560.12M	414.83M	-224.06M	-328.95M	238.62M
Balance Sheet
Total Assets	10.94B	12.01B	11.39B	10.84B	12.30B	6.54B
Cash, Cash Equivalents and Short-Term Investments	1.67B	2.99B	1.63B	881.48M	591.45M	2.13B
Total Debt	5.43B	6.16B	5.79B	5.81B	6.15B	2.25B
Total Liabilities	7.24B	7.92B	7.66B	7.75B	8.33B	2.88B
Stockholders Equity	3.71B	4.09B	3.74B	3.09B	3.97B	3.66B
Cash Flow
Free Cash Flow	1.27B	1.35B	1.07B	773.78M	732.98M	520.39M
Operating Cash Flow	1.32B	1.40B	1.09B	1.27B	778.51M	899.65M
Investing Cash Flow	-789.15M	-508.19M	-163.06M	-446.23M	-5.21B	-1.01B
Financing Cash Flow	-699.84M	20.52M	-305.25M	-529.49M	3.97B	528.07M

Jazz Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 128.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JAZZ, the sentiment is Positive. The current price of 128.02 is above the 20-day moving average (MA) of 120.80, above the 50-day MA of 115.78, and above the 200-day MA of 119.23, indicating a bullish trend. The MACD of 4.08 indicates Negative momentum. The RSI at 65.56 is Neutral, neither overbought nor oversold. The STOCH value of 80.45 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JAZZ.

Jazz Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HALO	79 Outperform	$8.58B	17.09	179.14%	―	34.97%	71.10%
CORT	69 Neutral	$7.52B	63.49	21.42%	―	25.71%	4.48%
JAZZ	64 Neutral	$7.87B	15.58	-10.84%	―	4.52%	-205.13%
TECH	64 Neutral	$8.31B	116.31	3.68%	0.60%	5.23%	-56.70%
ROIV	61 Neutral	$8.46B	1.93	-15.84%	―	-85.32%	-111.82%
RVMD	52 Neutral	$7.39B	―	-46.61%	―	-100.00%	-23.49%
Sector *	51 Neutral	$7.91B	-0.36	-41.71%	2.23%	23.45%	-1.86%

Jazz Pharmaceuticals Corporate Events

Jazz Pharmaceuticals Shareholders Approve Key Proposals

On July 24, 2025, Jazz Pharmaceuticals held its annual general meeting of shareholders in Dublin, Ireland, where four key proposals were voted on. The shareholders elected four directors to serve until 2028, ratified KPMG as independent auditors, approved executive compensation, and granted the board authority to issue shares without pre-emption rights, indicating strong shareholder support for the company’s strategic decisions.

Jazz Pharmaceuticals Appoints Renee Gala as New CEO

On July 8, 2025, Jazz Pharmaceuticals announced the appointment of Renee Gala as the new President and Chief Executive Officer, effective August 11, 2025. This leadership change follows a robust succession process and marks a significant milestone in the company’s long-term succession planning. Bruce Cozadd, the current CEO, will retire on September 12, 2025, but will continue as Chairperson of the Board. Gala, who has been with Jazz since 2020, has played a pivotal role in the company’s transformation and growth, and her appointment is expected to drive further value creation and sustainable growth for Jazz Pharmaceuticals.